We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall
Read MoreHide Full Article
Medtronic plc (MDT - Free Report) reported third-quarter fiscal 2021 adjusted earnings per share (EPS) of $1.29, beating the Zacks Consensus Estimate by 12.2%. Adjusted earnings however plunged 10.4% year over year. Currency-adjusted EPS came in at $1.35 for the quarter.
Without certain one-time adjustments — including restructuring, acquisition, amortization expenses and certain litigation charges — GAAP EPS was 94 cents, reflecting a 33.8% decline from the year-ago reported figure.
Total Revenues
Worldwide revenues in the reported quarter grossed $7.78 billion, down 1% on an organic basis (excluding the impacts of currency) but up 0.8% on a reported basis. The top line matched the Zacks Consensus Estimate.
In the quarter under review, U.S. sales (51% of total revenues) declined 2% year over year on a reported basis (same on an organic basis) to $3.94 billion. Non-U.S. developed market revenues totaled $2.52 billion (32% of total revenues), depicting a 6.1% improvement on a reported basis (down 0.2% on an organic basis).
Emerging market revenues (17% of total revenues) amounted to $1.31 billion, up 0.3% on a reported basis (up 0.8% organically).
Segment Details
The company currently generates revenues from four major segments, namely Cardiac and Vascular Group (“CVG”), Minimally Invasive TherapiesGroup (“MITG”), Restorative Therapies Group (“RTG”), and Diabetes Group.
CVG comprises Cardiac Rhythm & Heart Failure (“CRHF”), Coronary & Structural Heart (“CSH”), and Aortic & Peripheral Vascular divisions (“APV”). MITG includes Surgical Innovations (“SI”), and Respiratory, Gastrointestinal & Renal (“RGR”) divisions. RTG consists of Spine, Brain Therapies, Specialty Therapies and Pain Therapies segments, while Diabetes Group incorporates Intensive Insulin Management (“IIM”), Non-Intensive Diabetes Therapies (“NDT”) and Diabetes Service & Solutions (“DSS”) divisions.
In the fiscal third quarter, CVG revenues declined 5.9% at CER to $2.71 billion, reflecting the impact of the COVID-19 resurgence on procedure volumes in late December and January. CRHF sales totaled $1.37 billion, down 3.7% year over year at CER. Revenues from CSH were down 9.5% at CER to $873 million. APV revenues were down 5% at CER to $463 million.
In MITG, worldwide sales totaled $2.31 billion, marking a 4.6% year-over-year improvement at CER. Increased demand for COVID-19 related diagnostics and therapies was offset by the impact of the COVID-19 resurgence on procedure volumes in late December and January. Surgical Innovations declined 5.3% while RGR registered an improvement of 25.4% both at CER.
In RTG, worldwide revenues of $2.13 billion were down 0.8% year over year at CER, impacted by pandemic-led decline in procedure volumes. Cranial and Spinal Technologies reported 4.5% drop at CER. Sales in Specialty Therapies improved 3.2% while Neuromodulation were up 3.4% year over year at CER.
Revenues at the Diabetes group increased 0.8% at CER to $630 million.
Margins
Gross margin in the reported quarter contracted 261 basis points (bps) to 66.3% on a 3.1% decline in gross profit to $5.15 billion. Adjusted operating margin contracted 202 bps year over year to 25.9%. Selling, general and administrative expenses fell 1.9% to $2.54 billion, while research and development expenses increased 4.9% to $601 million.
Guidance
Due to the uncertainty spurred by the COVID-19 pandemic, this time too, Medtronic has decided not to provide any annual or quarterly financial guidance.
Our Take
While Medtronic’s third-quarter fiscal 2021 earnings were ahead of the Zacks Consensus Estimate, revenues came in line with the same. The company registered year-over-year decline in both the figures. Respiratory, Gastrointestinal, & Renal as well as Specialty Therapies, Neuromodulation and Diabetes Group registered year-over-year growth on an organic basis. However, performance of the rest of the business segments deteriorated.
The company’s performance was primarily impacted by deferred procedures due to the pandemic during December and January. Escalating costs and expenses put pressure on its margins.
However, the company reported sequential improvement in both revenues and earnings.
Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, which surpassed the Zacks Consensus Estimate by 33.6%.
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Further, fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.
AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny. The Zacks Consensus Estimate was loss of 2 cents per share. Additionally, revenues of $72.8 million beat the consensus mark by 8%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Bigstock
Medtronic's (MDT) Q3 Earnings Beat Estimates, Margins Fall
Medtronic plc (MDT - Free Report) reported third-quarter fiscal 2021 adjusted earnings per share (EPS) of $1.29, beating the Zacks Consensus Estimate by 12.2%. Adjusted earnings however plunged 10.4% year over year. Currency-adjusted EPS came in at $1.35 for the quarter.
Without certain one-time adjustments — including restructuring, acquisition, amortization expenses and certain litigation charges — GAAP EPS was 94 cents, reflecting a 33.8% decline from the year-ago reported figure.
Total Revenues
Worldwide revenues in the reported quarter grossed $7.78 billion, down 1% on an organic basis (excluding the impacts of currency) but up 0.8% on a reported basis. The top line matched the Zacks Consensus Estimate.
In the quarter under review, U.S. sales (51% of total revenues) declined 2% year over year on a reported basis (same on an organic basis) to $3.94 billion. Non-U.S. developed market revenues totaled $2.52 billion (32% of total revenues), depicting a 6.1% improvement on a reported basis (down 0.2% on an organic basis).
Emerging market revenues (17% of total revenues) amounted to $1.31 billion, up 0.3% on a reported basis (up 0.8% organically).
Segment Details
The company currently generates revenues from four major segments, namely Cardiac and Vascular Group (“CVG”), Minimally Invasive TherapiesGroup (“MITG”), Restorative Therapies Group (“RTG”), and Diabetes Group.
CVG comprises Cardiac Rhythm & Heart Failure (“CRHF”), Coronary & Structural Heart (“CSH”), and Aortic & Peripheral Vascular divisions (“APV”). MITG includes Surgical Innovations (“SI”), and Respiratory, Gastrointestinal & Renal (“RGR”) divisions. RTG consists of Spine, Brain Therapies, Specialty Therapies and Pain Therapies segments, while Diabetes Group incorporates Intensive Insulin Management (“IIM”), Non-Intensive Diabetes Therapies (“NDT”) and Diabetes Service & Solutions (“DSS”) divisions.
Medtronic PLC Price, Consensus and EPS Surprise
Medtronic PLC price-consensus-eps-surprise-chart | Medtronic PLC Quote
In the fiscal third quarter, CVG revenues declined 5.9% at CER to $2.71 billion, reflecting the impact of the COVID-19 resurgence on procedure volumes in late December and January. CRHF sales totaled $1.37 billion, down 3.7% year over year at CER. Revenues from CSH were down 9.5% at CER to $873 million. APV revenues were down 5% at CER to $463 million.
In MITG, worldwide sales totaled $2.31 billion, marking a 4.6% year-over-year improvement at CER. Increased demand for COVID-19 related diagnostics and therapies was offset by the impact of the COVID-19 resurgence on procedure volumes in late December and January. Surgical Innovations declined 5.3% while RGR registered an improvement of 25.4% both at CER.
In RTG, worldwide revenues of $2.13 billion were down 0.8% year over year at CER, impacted by pandemic-led decline in procedure volumes. Cranial and Spinal Technologies reported 4.5% drop at CER. Sales in Specialty Therapies improved 3.2% while Neuromodulation were up 3.4% year over year at CER.
Revenues at the Diabetes group increased 0.8% at CER to $630 million.
Margins
Gross margin in the reported quarter contracted 261 basis points (bps) to 66.3% on a 3.1% decline in gross profit to $5.15 billion. Adjusted operating margin contracted 202 bps year over year to 25.9%. Selling, general and administrative expenses fell 1.9% to $2.54 billion, while research and development expenses increased 4.9% to $601 million.
Guidance
Due to the uncertainty spurred by the COVID-19 pandemic, this time too, Medtronic has decided not to provide any annual or quarterly financial guidance.
Our Take
While Medtronic’s third-quarter fiscal 2021 earnings were ahead of the Zacks Consensus Estimate, revenues came in line with the same. The company registered year-over-year decline in both the figures. Respiratory, Gastrointestinal, & Renal as well as Specialty Therapies, Neuromodulation and Diabetes Group registered year-over-year growth on an organic basis. However, performance of the rest of the business segments deteriorated.
The company’s performance was primarily impacted by deferred procedures due to the pandemic during December and January. Escalating costs and expenses put pressure on its margins.
However, the company reported sequential improvement in both revenues and earnings.
Zacks Rank & Recent Releases
Medtronic currently has a Zacks Rank #3 (Hold).
Companies in the broader medical space that have already announced quarterly results include Hologic, Inc. (HOLX - Free Report) , Abbott Laboratories (ABT - Free Report) and AngioDynamics, Inc. (ANGO - Free Report) , each presently carrying a Zacks Rank#2 (Buy).You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Hologic reported first-quarter fiscal 2021 adjusted EPS of $2.86, which surpassed the Zacks Consensus Estimate by 33.6%.
Abbott reported fourth-quarter 2020 adjusted EPS of $1.45, which surpassed the Zacks Consensus Estimate by 6.6%. Further, fourth-quarter worldwide sales of $10.7 billion outpaced the consensus mark by 7.9%.
AngioDynamics reported second-quarter fiscal 2021 adjusted EPS of a penny. The Zacks Consensus Estimate was loss of 2 cents per share. Additionally, revenues of $72.8 million beat the consensus mark by 8%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>